Oncolys BioPharma Inc.
Notice regarding the recognition of non-operating income and non-operating expenses
For the second quarter cumulative period of the 2026 fiscal year (2026/1/1-2026/6/30), non-operating income of 2000 ten thousand yen and non-operating expenses of 1300 ten thousand yen were recognized. The primary driver is gains from foreign exchange remeasurement of foreign-currency assets, including gains from currency fluctuations. Interest expenses and other costs were also recorded for the period. The impact on performance is described in the Earnings Report for the fiscal year ending December 2026 published on August 7, 2026 (Japanese accounting standards, non-consolidated).
Key Figures
- Non-operating income: 20百万円
- Non-operating expenses: 13百万円
- Q2-Q4 additional recognition: Non-operating income 8百万円 / Non-operating expenses 8百万円
AI要約
Overview
This report specifies the recognition of non-operating income and non-operating expenses for the second quarter cumulative period of the 2026 fiscal year (January 1, 2026 to June 30, 2026). The main non-operating income comes from foreign exchange gains due to remeasurement of foreign-currency assets, totaling 20百万円 (with an additional 8百万円 recognized in Q2-Q4). Non-operating expenses total 13百万円 (with an additional 8百万円 recognized in Q2-Q4), centered on interest expenses. The impact on performance is described in the separately published Earnings Summary.
Future impact and notes
The impact on performance from these non-operating income and expenses is explained in the August 7, 2026 release of the Earnings Summary for the 2026 December interim period (Japanese standards, non-consolidated). These are temporary factors such as foreign exchange gains, and their effect on full-year performance follows what is stated in that Earnings Summary. Specific amounts and future outlook are not included in this document; any questions should refer to the Earnings Summary supplementary information.
Oncoris Biopharma Co., Ltd.
Company overview · Stock price · Financial data · All IR
